loading
Sagimet Biosciences Inc stock is traded at $3.9676, with a volume of 66,230. It is up +3.38% in the last 24 hours and down -1.12% over the past month. Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$3.85
Open:
$3.98
24h Volume:
66,230
Relative Volume:
0.07
Market Cap:
$123.95M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-3.3454
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+13.39%
1M Performance:
-1.12%
6M Performance:
+26.75%
1Y Performance:
-12.72%
1-Day Range:
Value
$3.9041
$4.0303
1-Week Range:
Value
$3.50
$4.06
52-Week Range:
Value
$2.39
$7.38

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name
Name
Sagimet Biosciences Inc
Name
Phone
(650) 561-8600
Name
Address
155 BOVET RD., SUITE 303, SAN MATEO
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SGMT's Discussions on Twitter

Compare SGMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SGMT
Sagimet Biosciences Inc
3.95 123.95M 0 -29.25M -22.80M -1.186
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
511.71 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
670.14 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
616.99 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.66 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
263.54 28.62B 3.81B -644.79M -669.77M -6.24

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-06-24 Initiated Oppenheimer Outperform
Nov-12-24 Initiated UBS Buy
Jun-28-24 Downgrade Goldman Buy → Neutral
May-02-24 Initiated H.C. Wainwright Buy
Mar-25-24 Initiated Leerink Partners Outperform
Aug-08-23 Initiated Goldman Buy
Aug-08-23 Initiated JMP Securities Mkt Outperform
Aug-08-23 Initiated Piper Sandler Overweight
Aug-08-23 Initiated TD Cowen Outperform
View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

pulisher
01:04 AM

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World

01:04 AM
pulisher
Mar 17, 2025

Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 17, 2025

HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World

Mar 17, 2025
pulisher
Mar 13, 2025

Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks

Mar 13, 2025
pulisher
Mar 12, 2025

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld Online

Mar 12, 2025
pulisher
Mar 12, 2025

Sagimet Biosciences Inc. (SGMT) reports earnings - Quartz

Mar 12, 2025
pulisher
Mar 12, 2025

Sagimet Biosciences Inc. SEC 10-K Report - TradingView

Mar 12, 2025
pulisher
Mar 12, 2025

Sagimet's FDA Breakthrough Drug Enters Phase 3 Trials with $158M War Chest - StockTitan

Mar 12, 2025
pulisher
Mar 12, 2025

Promising Developments in Sagimet Biosciences: IND Clearance for TVB-3567 and Ongoing Success of Denifanstat - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567 - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials -March 11, 2025 at 10:46 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Sagimet Biosciences receives FDA nod to begin testing its therapy for acne -March 11, 2025 at 09:38 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - SEC.gov

Mar 11, 2025
pulisher
Mar 11, 2025

Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567 - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Sagimet Biosciences Announces Clearance of IND for FASN - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for ... - The Bakersfield Californian

Mar 11, 2025
pulisher
Mar 11, 2025

FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha

Mar 07, 2025
pulisher
Feb 25, 2025

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey

Feb 25, 2025
pulisher
Feb 24, 2025

10 Best Get Rich Quick Stocks To Invest In - Insider Monkey

Feb 24, 2025
pulisher
Feb 23, 2025

Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

10 Hot Penny Stocks to Buy Now - Insider Monkey

Feb 22, 2025
pulisher
Feb 22, 2025

Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -

Feb 22, 2025
pulisher
Feb 22, 2025

Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now - Insider Monkey

Feb 22, 2025
pulisher
Feb 21, 2025

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Feb 21, 2025
pulisher
Feb 19, 2025

Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... - The Bakersfield Californian

Feb 19, 2025
pulisher
Feb 19, 2025

Could This New MASH Drug Transform Liver Disease Treatment? Key Phase 2b Results Revealed - StockTitan

Feb 19, 2025
pulisher
Feb 14, 2025

FY2024 Earnings Estimate for SGMT Issued By Leerink Partnrs - MarketBeat

Feb 14, 2025
pulisher
Feb 11, 2025

Technical analysis of Sagimet Biosciences Inc (SGMT) stock chart patterns - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

FY2024 Earnings Forecast for SGMT Issued By Leerink Partnrs - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Keeping an Eye on Sagimet Biosciences Inc (SGMT) After Insider Trading Activity - Knox Daily

Feb 10, 2025
pulisher
Feb 08, 2025

Sagimet Biosciences Inc (NASDAQ:SGMT) Up 47.7% Since 52-Week Low; YTD Rose 1.56% – Here’s What You Need To Do – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Equities Analysts Issue Forecasts for SGMT FY2029 Earnings - MarketBeat

Feb 08, 2025
pulisher
Feb 06, 2025

Prepare Yourself for Liftoff: Sagimet Biosciences Inc (SGMT) - SETE News

Feb 06, 2025
pulisher
Feb 05, 2025

Sagimet Biosciences Inc (SGMT)’s results reveal risk - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Analytical Overview: Sagimet Biosciences Inc (SGMT)’s Ratios Tell a Financial Story - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks - Yahoo Finance

Feb 04, 2025
pulisher
Feb 03, 2025

Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity - TipRanks

Feb 03, 2025
pulisher
Feb 02, 2025

What's Going On With Sagimet Biosciences Stock On Thursday? - MSN

Feb 02, 2025
pulisher
Feb 01, 2025

JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World

Feb 01, 2025
pulisher
Feb 01, 2025

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 01, 2025
pulisher
Jan 27, 2025

This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jan 27, 2025
pulisher
Jan 26, 2025

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 26, 2025

Sagimet Biosciences Inc Stock (SGMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Sagimet Biosciences Inc Stock (SGMT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Martins Eduardo Bruno
Chief Medical Officer
Jul 19 '24
Sale
3.10
8,357
25,910
81,213
Rozek Elizabeth
General Counsel and CCO
Jul 19 '24
Sale
3.10
10,914
33,830
160,506
Kemble George
Executive Chairman
Jul 19 '24
Sale
3.10
14,062
43,605
142,318
Happel David
President & CEO
Mar 26 '24
Buy
5.27
12,100
63,731
639,200
$79.70
price up icon 0.37%
$315.01
price down icon 0.88%
$33.42
price up icon 0.09%
$19.60
price down icon 1.10%
$98.86
price up icon 0.44%
biotechnology ONC
$264.15
price down icon 1.17%
Cap:     |  Volume (24h):